UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): NOVEMBER 8, 2006
--------------------------
ENZO BIOCHEM, INC.
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
NEW YORK
--------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
001-09974 13-2866202
--------------------------------------------------------------------------------
(Commission File Number) (IRS Employer Identification No.)
527 MADISON AVENUE
NEW YORK, NEW YORK 10022
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(212) 583-0100
--------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (SEE General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.03. AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN
FISCAL YEAR.
-------------------------------------------------------------------
(a) On November 8, 2006, the Board of Directors of Enzo Biochem, Inc.
voted by unanimous written consent to add a new Section 17 to Article II of
Enzo's Bylaws, effective immediately, to provide that the total cumulative
length of time that any Outside Director (a member of the Board who is not an
officer or employee of Enzo) may serve on the Board shall be limited to a
maximum of three three-year terms, whether consecutively or in total, plus any
portion of an earlier three-year term that such Outside Director may have been
appointed to serve.
A copy of Enzo's Bylaws, as amended, is attached to this Report as
Exhibit 3.1 and is incorporated herein by reference.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
----------------------------------
(c) EXHIBITS.
EXHIBIT NO. DESCRIPTION
----------- ------------
3.1 Amended and Restated Bylaws of Enzo Biochem, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
ENZO BIOCHEM, INC.
Date: November 13, 2006 By: /s/ ELAZAR RABBANI
-----------------------------------
Dr. Elazar Rabbani, Ph.D.
Chairman of the Board and Chief
Executive Officer
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
------------ ------------
3.1 Amended and Restated Bylaws of Enzo Biochem, Inc.